Rehabilitation ProgramQTX-001NCT07850518
Magnetic Mitohormesis (MM) Treatment in Stroke Rehabilitation.
A study testing Quantum Magnetic in people with Rehabilitation Program and Stroke Rehabilitation, run by QuantumTX Pte Ltd at 2 sites in Singapore.
Trial summary
Although sarcopenia is commonly seen in stroke patients with a prevalence rate of 42%, relevant research studies are more in geriatric population rather than in stroke patients. Beside conventional functional physiotherapy, improving blood circulation, improving cellular oxygenation and reducing inflammation by MM… Read more about this study
- Who is it for?
- Ages 30 to 70 years
- Conditions the study is for
- Rehabilitation Program, Stroke Rehabilitation, Physical Functional Performance
- What is being tested?
- Quantum Magnetic
- Type of treatment
- Medical device
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 60 participants
- Where
- 2 sitesSingapore
- Study dates
- 20 Mar 2024to 1 Apr 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 30 to 70 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Adult age 30 - 70 years
- Diagnosis of stroke(s), with most recent stroke at least 10 weeks prior to study participation
- Functional Ambulation Categories (FAC): 2 to 3
- Normal cognition with Montreal Cognitive Assessment (MOCA) score 21
- Intact language skills to comprehend and follow directions as per Investigator's assessment.
- Individuals must agree to comply with all study visits and procedures.
- Individuals must freely provide consent to study participation.
Who cannot join
- Contraindications to PEMF therapy, which include electronic implants (e.g., pacemaker, implantable cardioverter defibrillator, cochlear implants)
- History of neurological disorder (e.g Seizure, Myasthenia Gravis, Multiple Sclerosis and Myopathies) other than stroke
- Pregnant and lactating women
- Simultaneously receiving standard care
Trial locations and contacts
2 sites in 1 country.
Singapore2 sites
Stroke Support Station (S3) - Jurong Point
Singapore, Singapore, 648886
Stroke Support Station (S3) - Enabling Village
Singapore, 159053
About this study
Although sarcopenia is commonly seen in stroke patients with a prevalence rate of 42%, relevant research studies are more in geriatric population rather than in stroke patients. Beside conventional functional physiotherapy, improving blood circulation, improving cellular oxygenation and reducing inflammation by MM therapy is supposed to improve muscle atrophy after stroke, thus enhancing the functional recovery.
The investigators are not investigating the direct effect of MM therapy on muscle mass in the current study, but are looking at the function outcomes and changes in quality of life of patients after MM therapy, which is more relevant to the clinical practice in stroke recovery.
Read more
Based on literature review and previous studies, stroke patients might benefit from MM therapy by enhancing the outcomes in functional mobility and measures of quality of life, so the purpose of this study is to investigate if MM treatment could boost the functional recovery and muscle strength on top of the effects from the conventional physiotherapy.
The findings of this study might improve the medical knowledge on how MM therapy could affect clinical function outcome in post-stroke rehabilitation and provide alternative method to enhance motor recovery.
Read the detailed description
In this clinical trial, participants will be exposed to MM fields for 10 minutes per week for a maximum of 12 weeks in addition to standard clinical follow-up.
The route of administration, dosage, and frequency are based on studies done in vitro and in vivo models in mice and in adults. At the Swiss Federal Institute of Technology (ETH) in Zurich, the inventors of the MM device were contracted by the Swiss Agency (Bundesamt für Gesundheit, BAG) to test for the safety of diverse PEMF-delivery devices. The MM device was shown to be non-cytotoxic and non-transforming and produces pulsed magnetic fields at flux densities up to 2 mT peak and consists of a privately designed control unit and coil system. For clinical purposes the MM device will be working at less than this value (1.5 mT). Previous data showed enhancement in muscle with only 10 minutes of non-invasive MM fields exposure per week in mice.
In previous human trials, on healthy individuals following ACL-reconstructive surgery, exposure to MM fields showed muscle metabolic improvement and reduced muscle breakdown (measured effects of MM on serum ceramides, lysophosphatidylcholine, TNNT1 and P3NP), myokine upregulation reflecting improved muscle regeneration (measured effects of MM on Follistatin, IGF1, FGF21, IL-6). This was in response to two 10 minutes MM exposures per week on the operated leg. These findings helped to set up the treatment regime for the MM device to impose myogenic effects, including exposure time per session, number of treatment sessions and duration of treatment.
- Being tested
- Quantum Magnetic, Sham Mode MM Device
- Keywords
- Magnetic Mitohormesis (MM) treatment in Stroke Rehabilitation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Quantum MagneticDevice
The intervention will be held at the stipulated study sites. Participants in the intervention group will be exposed to active pulse electromagnetic field treatment by a tested device. The active pulse electromagnetic field device does not produce heat or cause any sensation to the tissue which allows the participants to be blinded to the treatment.
Sham Mode MM DeviceDevice
Sham sessions help to maintain participant blinding while eliminating the therapeutic electromagnetic field exposure. The sham device mode reproduces the visual and auditory characteristics of active MM treatment, including display screens, indicator lights, operational sounds, and treatment duration timer. However, no therapeutic electromagnetic field is generated.
MM devices can be configured to deliver either active treatment or sham treatment through the use of an RFID card reader. RFID cards are pre-programmed and randomised to correspond to either an active or sham session. When the assigned RFID card is tapped on the device, the corresponding treatment protocol is automatically initiated. Therefore double-blinding of both participants and study team / operators / assessors is possible
| Study group | Role | What they receive |
|---|---|---|
| Sham group | Sham comparator | control group receiving the placebo Receives: Device: Sham Mode MM Device |
| Treated Group | Active comparator | Intervention group receiving MM therapy Receives: Device: Quantum Magnetic |
What is being measured
The primary outcome is the main question the study is designed to answer.
Safety - Safety profile and Number of participants with treatment-related AEs and SAEs
To assess safety of MM in subacute stroke patients with moderately affected mobility for functional mobility training, assessed through number of participants with treatment-related adverse events, and safety evaluation of the adverse event (AE) profiles.
Measured: 16 weeks
Secondary outcomes (4)
Mobility - 10-Metre Walk Test
Gait speed assessed by 10-Metre Walk Test, administered by physiotherapist.
Measured: From baseline to 16 weeks
Mobility - 5 Times Sit To Stand Test
Lower limb strength assessed through the 5TSTS administered by a physiotherapist.
Measured: From baseline to 16 weeks
Mobility - Timed Up and Go
Dynamic balance assessed through the TUG administered by a physiotherapist.
Measured: From baseline to 16 weeks
Quality of Life - EuroQoL-5D-5L
EQ-5D-5L is an established tool for assessing the general health status of individuals across a wide array of health conditions and treatments. It measures health outcomes in five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is rated on a five-level scale, from no problems (level 1) to extreme problems (level 5), facilitating a comprehensive evaluation of a patient's health-related quality of life. The total score is derived by converting the individual dimension scores into a single summary index value, reflecting the overall health status, with higher scores indicating better health outcomes.
Measured: From baseline to 16 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Sep 2026
- Study start20 Mar 2024
- Primary completion1 Mar 2026
- Study completion1 Apr 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Rehabilitation ProgramStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 60 participants (actual)
Sponsor and investigators
- Lead sponsor
- QuantumTX Pte Ltd
- Sponsor type
- Research network
- Responsible party
- Sponsor
- Investigators
- Gobinathan Chandran, Principal investigator, National University Hospital, Singapore
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07850518
- Sponsor's protocol ID
- QuantumTX
- Acronym
- QTX-001
- Status last verified
- Sep 2026
- First submitted
- 24 Jun 2024
- Last updated
- 6 Oct 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 6 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Magnetic Mitohormesis (MM) Treatment in Stroke Rehabilitation.
- ClinicalTrials.gov ID
- NCT07850518
- Acronym / sponsor ID
- QTX-001 / QuantumTX
- Keywords
- Magnetic Mitohormesis (MM) treatment in Stroke Rehabilitation
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 60 participants (actual)
- Lead sponsor
- QuantumTX Pte LtdResearch network
- Study start
- 20 Mar 2024 (actual)
- Primary completion
- 1 Mar 2026 (actual)
- Study completion
- 1 Apr 2026 (actual)
- First posted
- 30 Sep 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Although sarcopenia is commonly seen in stroke patients with a prevalence rate of 42%, relevant research studies are more in geriatric population rather than in stroke patients. Beside conventional functional physiotherapy, improving blood circulation, improving cellular oxygenation and reducing inflammation by MM therapy is supposed to improve muscle atrophy after stroke, thus enhancing the functional recovery.
The investigators are not investigating the direct effect of MM therapy on muscle mass in the current study, but are looking at the function outcomes and changes in quality of life of patients after MM therapy, which is more relevant to the clinical practice in stroke recovery.
Based on literature review and previous studies, stroke patients might benefit from MM therapy by enhancing the outcomes in functional mobility and measures of quality of life, so the purpose of this study is to investigate if MM treatment could boost the functional recovery and muscle strength on top of the effects from the conventional physiotherapy.
The findings of this study might improve the medical knowledge on how MM therapy could affect clinical function outcome in post-stroke rehabilitation and provide alternative method to enhance motor recovery.
Detailed description
In this clinical trial, participants will be exposed to MM fields for 10 minutes per week for a maximum of 12 weeks in addition to standard clinical follow-up.
The route of administration, dosage, and frequency are based on studies done in vitro and in vivo models in mice and in adults. At the Swiss Federal Institute of Technology (ETH) in Zurich, the inventors of the MM device were contracted by the Swiss Agency (Bundesamt für Gesundheit, BAG) to test for the safety of diverse PEMF-delivery devices. The MM device was shown to be non-cytotoxic and non-transforming and produces pulsed magnetic fields at flux densities up to 2 mT peak and consists of a privately designed control unit and coil system. For clinical purposes the MM device will be working at less than this value (1.5 mT). Previous data showed enhancement in muscle with only 10 minutes of non-invasive MM fields exposure per week in mice.
In previous human trials, on healthy individuals following ACL-reconstructive surgery, exposure to MM fields showed muscle metabolic improvement and reduced muscle breakdown (measured effects of MM on serum ceramides, lysophosphatidylcholine, TNNT1 and P3NP), myokine upregulation reflecting improved muscle regeneration (measured effects of MM on Follistatin, IGF1, FGF21, IL-6). This was in response to two 10 minutes MM exposures per week on the operated leg. These findings helped to set up the treatment regime for the MM device to impose myogenic effects, including exposure time per session, number of treatment sessions and duration of treatment.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Sham group | Sham comparator | Device: Sham Mode MM Devicecontrol group receiving the placebo |
| Treated Group | Active comparator | Device: Quantum MagneticIntervention group receiving MM therapy |
Who may qualify
- Ages
- 30 to 70 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Adult age 30 - 70 years
- Diagnosis of stroke(s), with most recent stroke at least 10 weeks prior to study participation
- Functional Ambulation Categories (FAC): 2 to 3
- Normal cognition with Montreal Cognitive Assessment (MOCA) score 21
- Intact language skills to comprehend and follow directions as per Investigator's assessment.
Key exclusion criteria (4 listed)
- Contraindications to PEMF therapy, which include electronic implants (e.g., pacemaker, implantable cardioverter defibrillator, cochlear implants)
- History of neurological disorder (e.g Seizure, Myasthenia Gravis, Multiple Sclerosis and Myopathies) other than stroke
- Pregnant and lactating women
- Simultaneously receiving standard care
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Quantum MagneticThe intervention will be held at the stipulated study sites. Participants in the intervention group will be exposed to active pulse electromagnetic field treatment by a tested device. The active pulse electromagnetic field device does not produce heat or cause any sensation to the tissue which allows the participants to be blinded to the treatment. | Device | Treated Group |
| Sham Mode MM DeviceSham sessions help to maintain participant blinding while eliminating the therapeutic electromagnetic field exposure. The sham device mode reproduces the visual and auditory characteristics of active MM treatment, including display screens, indicator lights, operational sounds, and treatment duration timer. However, no therapeutic electromagnetic field is generated. MM devices can be configured to deliver either active treatment or sham treatment through the use of an RFID card reader. RFID cards are pre-programmed and randomised to correspond to either an active or sham session. When the assigned RFID card is tapped on the device, the corresponding treatment protocol is automatically initiated. Therefore double-blinding of both participants and study team / operators / assessors is possible | Device | Sham group |
Primary outcome
Safety - Safety profile and Number of participants with treatment-related AEs and SAEs
Time frame: 16 weeks
To assess safety of MM in subacute stroke patients with moderately affected mobility for functional mobility training, assessed through number of participants with treatment-related adverse events, and safety evaluation of the adverse event (AE) profiles.
4 secondary outcomes
Mobility - 10-Metre Walk Test
Time frame: From baseline to 16 weeks
Mobility - 5 Times Sit To Stand Test
Time frame: From baseline to 16 weeks
Mobility - Timed Up and Go
Time frame: From baseline to 16 weeks
Quality of Life - EuroQoL-5D-5L
Time frame: From baseline to 16 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Oct 2026.
- Individual participant dataSharing planned: No
Related trials for Rehabilitation Program
Not yet recruiting
Feasibility of a Robot-Guided Active Play Intervention for Children With Cerebral Palsy
Cerebral Palsy
Not yet recruiting
Effects of Hip Hinge Exercises on Pain, Range of Motion and Functional Disability in Non-specific Low Back Pain.
Low Back Pain
Recruiting
Web-Based Tele-Rehabilitation Using Action Observation and Mirror Therapy for Subacute Stroke: A Randomized Controlled Trial
Stroke, Upper Extremity Paresis
Recruiting
MyHand-SCI: An Active Hand Orthosis for Spinal Cord Injury
Spinal Cord Injuries, Tetraplegia
Recruiting
Sensory Integration Therapy vs Conventional Physical Therapy in Children With Mixed Cerebral Palsy
Cerebral Palsy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Gobinathan Chandran principal investigator
National University Hospital, Singapore
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Quantum Magnetic in people with Rehabilitation Program and Stroke Rehabilitation, run by QuantumTX Pte Ltd at 2 sites in Singapore.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 6 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in Singapore. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Safety - Safety profile and Number of participants with treatment-related AEs and SAEs (time frame: 16 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Oct 2026.